Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion

Japanese Journal of Clinical Oncology

Volumn 29, Issue 9, 1999, Pages 421-424

  Lai, Ruay Sheng ^a,b   Chen, Chin Chung ^a   Lee, Pei Ching ^c   Lu, Jau Yeong ^a,b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

Author keywords

CYFRA 21 1; Cytokeratin; Pleural effusion; Tumor marker

Indexed keywords

ANTIGEN CYFRA21.1; CARCINOEMBRYONIC ANTIGEN; KERATIN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PLEURA EFFUSION; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA;

ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; HUMANS; KERATINS; LUNG NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0033192173     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.9.421     Document Type: Review

References (28)

1. Prakash UB, Reiman HM. Comparison of needle biopsy with cytological analysis for the evaluation of pleural effusion: an analysis of 414 cases. Mayo Clin Proc 1985;60:158-64.
2. Edmondstone WM. Investigation of pleural effusion: comparison between fibreoptic thoracoscopy, needle biopsy and cytology. Respir Med 1990;84:23-6.
3. Harris RJ, Kavuru MS, Rice TW, Kieby TJ. The diagnostic and therapeutic utility of thoracoscopy. Chest 1995;198:828-41.
4. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and culture cells. Cell 1982;31:11-24.
5. Bartek J, Bartkova J, Schneider J, Taylor-Papadimitriou J, Kovarik J, Rejthar A. Expression of monoclonal antibody-defined epitopes of keratin 19 in human tumors and culture cells. Eur J Cancer Clin Oncol. 1986;22:1441-52.
6. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53:61-6.
7. Lai R-S, Hsu H-K, Lu J-Y, Ger L-P, Lai N-S. CYFRA 21-1 ELISA. Evaluation as a tumor marker in non-small cell lung cancer. Chest 1996;109:995-1000.
8. Rastel D, Ramaioli A, Cornillie F, Thirion B. CYFRA 21-1, a sensitive and specific new tumor marker for squamous cell lung cancer. Report of the first European multicenter evaluation. Eur J Cancer 1994;30A:601-6.
9. Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S. Assessment of serum CYFRA 21-1 in lung cancer. Cancer 1996;77:1274-7.
10. Rapellino M, Niklinski J, Pecchio F, Furman M, Baldi S, Chyczewski L, et al. CYFRA 21-1 as a tumor marker for bronchogenic carcinoma. Eur Respir J 1995;8:407-10.
11. Light RW. A new classification of parapneumonc effusion and empyema. Chest 1995;108:299-301.
12. Brown RW, Clark GM, Tandon AK, Allred DC. Multiple marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993;24:347-54.
13. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B, Estenoz-Alfaro J. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3 and CA 19-9 assay in pleural fluid. Cancer 1996;78:736-40.
14. Light RW. Malignant pleural effusion. In: Light RW, editor. Pleural Disease. 3rd ed. Baltimore: Williams and Wilkins 1995;94-116.
15. Garcia-Pachon E, Padilla-Navas I, Dosda D, Miralles-Llopis A. Elevated level of carcinoembryonic antigen in nonmalignant pleural effusion. Chest 1997;111:643-7.
16. Broers JL, Ramaekers FC, Rot MK, Oostendorp T, Huysmans A, van Muijen GN, et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 1988;48:3221-9.
17. Ho S, Leung WT, Yuen J, Johnson PJ. Serum level of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy. Eur J Cancer 1996;32B:377-80.
18. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997;79:1647-55.
19. Senga Y, Kimura G, Hattori T, Yoshida K. Clinical evaluation of soluble cytokeratin 19 fragment (CYFRA 21-1) in serum and urine of patients with bladder cancer. Urology 1996;48:703-10.
20. Bonfrer JM, Gaarenstroom KN, Korse CM, Van Bunningen BN, Kenemans P. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Anticancer Res 1997;17:2329-34.
21. Bonfrer JM, Schouwink JH, Korse CM, Baas P. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 1997;17:2971-4.
22. Salama G, Miedouge M, Rouzaud P, Mauduyt MA, Puiazon MC, Vincent C, et al. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 1998;77:472-6.
23. Romero S, Fernandez C, Arriero JM, Espasa A, Candela A, Martin C, et al. CEA, CA 15-3, CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996;9:17-23.
24. Toumbis M, Rasidakis A, Passalidou E, Kalomenidis J, Alchanatis M, Orphanidou D, et al. Evaluation of CYFRA 21-1 in malignant and benign pleural effusion. Anticancer Res 1996;16:2101-4.
25. Satoh H, Sumi M, Yagyu H, Ishikawa H, Sayama T, Naitoh T, et al. Clinical evaluation of CYRA 21-1 in malignant pleural effusion. Oncology 1995;52:211-14.
26. Sahn SA. State of art. The pleura. Am Rev Respir Dis 1988;138:184-234.
27. Larocca PJ, Rheunwald JG. Coexpression of simple epithelial keratins and vimentin by human mesothelium and mesothelioma in vivo and in culture. Cancer Res 1984;44:2991-9.
28. Shimokata K, Niwa Y, Yamamoto M, Sasou H, Morishita M. Pleural fluid neuron-specific enolase. A useful diagnostic marker for small cell lung cancer pleurisy. Chest 1989;95:602-3.